Introduction
Vaccinia viruses (VACVs) are well-studied members of the genus Orthopoxvirus within the family Poxviridae. Vaccinia was used as live vaccine during the World Health Organization (WHO) smallpox eradication program between 1966 and 1980 (Fenner et al., 1988) . MVA is an attenuated vaccinia virus strain produced by repeated passaging of chorioallantois vaccinia virus Ankara (CVA) in primary chicken embryo fibroblasts (Mayr et al., 1978 ) that has been used as an experimental vaccine in preventive smallpox vaccination studies with over 120,000 people (Stickl et al., 1974) .
According to German genetic engineering regulations, genetic engineering operations are classified into four categories called "Sicherheitsstufen" or, in accordance with directive 2009/41/EC (EU, 2009), containment levels (CL), according to their risk to human health and the environment. Containment level 1 (CL1) corresponds to no risk, CL2 to low risk, CL3 to moderate risk, and CL4 to high risk. The classification into containment levels is, among other things, dependent on the safety-relevant properties of (i) the donor organism, (ii) the inserted genetic material of the donor organism, (iii) the vector system used, (iv) the recipient organism, and (v) the resulting genetically modified organism.
Organisms that are used as donor and recipient organisms for genetic engineering operations are classified into risk groups in accordance with directive 2000/54/EC (EU, 2000) . Vaccinia exhibits a wide host range and is able to efficiently replicate in human cells, and laboratory-acquired VACV infections have been described (Isaacs, 2012) . In contrast, MVA exhibits a narrow host range and is not able to replicate in human cells. Therefore, VACV is classified as a risk group 2 biological agent, whereas the MVA strain is risk group 1 (ZKBS, 1997; ZKBS, 2002) .
In the same legal context, genetic engineering operations with recombinant VACVs carrying heterologous genes that do not increase their hazard potential are assigned to S2 (low risk), whereas genetic engineering operations with recombinant MVA carrying heterologous genes that neither alter their host spectrum nor increase their hazard potential are assigned into S1 (no risk) (Verheust et al., 2012; ZKBS, 1997) .
In the past 3 decades, VACVs including MVA became widely used vectors for the expression of heterologous genes in eukaryotic cells. The first recombinant VACV was published in 1982 (Mackett et al., 1982) . Insertion of heterologous genes into vaccinia viral genomes is performed by homologous recombination, which is usually achieved by infection of target cells followed by transfection of a selectable recombination plasmid. Vaccinia recombination plasmids consist of a heterologous gene under the control of a VACV-specific promoter element, flanked by homologous VACV DNA sequences that allow insertion into predefined loci of the viral genome. Clonal selection by several rounds of plaque purification yields the desired recombinant virus. The same applies for MVA, which was genetically modified for the first time in 1992, a decade after the generation of the first recombinant VACV (Sutter & Moss, 1992) . Alternatively, ever since the early 2000s, bacterial artificial chromosome (BAC) technology has been available for genetic manipulation of vaccinia and MVA genomes in E. coli using bacteriophage λ mediated recombination (Cottingham & Gilbert, 2010; Domi & Moss, 2002; Domi & Moss, 2005; Tischer et al., 2006) .
Multiplex ligation-dependent probe amplification (MLPA) is a PCR-based method originally developed for diagnosis of genetic disorders in humans (Schouten et al., 2002) . It is based on the use of bipartite sequence-specific probes with a characteristic number of base pairs. After hybridization of the respective probes to the specific target sequence, they are covalently linked by a ligation step and subsequently PCR-amplified utilizing universal fluorescence dye-labelled primers. Following PCR, MLPA products are separated by capillary gel electrophoresis for fragment length analysis depending on their unique fragment size. MLPA technology combines high multiplex ability www.absa.org
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with sensitivity comparable to quantitative real-time PCR (Wolffs et al., 2009) . In contrast to real-time multiplex assays, which are mostly restricted to detection of up to four or five targets in one reaction, depending on the number of channels available in the PCR machine utilized, MLPA allows simultaneous detection of up to 40 different targets with the use of a single primer-dye set (Schouten et al., 2002) . This study used synthetic probes, thus allowing multiplex ability from about 15 probe sets (De Smet et al., 2012) .
To differentiate between MVA and other VACV strains, this study took advantage of the fact that MVA lost about 15% of its genome as compared to other vaccinia viruses with six described major deletion regions (Del-I, -II, -III, -IV, -V, and -VI) (Kremer et al., 2012; Meyer et al., 1991) . Differentiation is achieved by the combination of three MLPA probe pairs that specifically bind to VACV target sequences that are missing in the MVA genome (C4L, K1L, and A52R-A53R IGR) and two MLPA probe pairs that bind to pan-vaccinia virus target sequences present in all vaccinia viral genomes (E3L and C23L) ( Figure  1 , Table 1 ).
To check for eight different predefined integration loci (F14.5L, J2R, F13L, A56R, I4L, A44L, Del-III, and D4R- Table 1 ) that are frequently used for the construction of recombinant vaccinia viruses by homologous recombination (Blasco & Moss, 1995; Carroll et al., 1998; Chakrabarti et al., 1985; Earl et al., 2001; Jimenez de Oya et al., 2012; Overwijk et al., 1998; Ricci et al., 2011; Wyatt et al., 1996; Zhang et al., 2009 ), a second set of MLPA probes was designed. The identification of an integration event into one of the eight loci is based on the fact that after the insertion of a heterologous gene, the wild type genome sequence is altered in between the flanking homologous sites (Earl et al., 2001) , resulting in no detectable MLPA-product. Once a particular integration event has been identified, the inserted heterologous gene can be amplified and sequenced by standard methods. Taken together, the authors have developed a MLPAbased method allowing the differentiation between human pathogenic vaccinia viruses and attenuated MVA strains. Additionally, eight predefined integration loci which are frequently used for the genetic engineering of recombinant vaccinia viruses, including MVA, can be tested for alterations in their sequence.
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Materials and Methods
Assay Principle
To differentiate between MVA and other vaccinia viruses, two pan-vaccinia virus targets (present in MVA and VACV) and three vaccinia virus-specific target sequences are detected in parallel by specific MLPA probes that are subsequently PCR-amplified and separated by capillary electrophoresis.
To check the integrity of eight different integration loci frequently used for the construction of recombinant vaccinia viruses by homologous recombination, a second set of MLPA probes was implemented to the assay. The alteration of any of those loci due to insertion of a heterologous gene results in loss of the respective MLPA product. Potential integration events can subsequently be identified by conserved sequencing primers. Amplicon Size (bp) 
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F14.5L 1 V/M GLV-1h68 c 94 J2R (TK e ) 2 V / M VV-Δ-ORF2- Myc-His 98 F13L 3 V/M vRB12 103 A56R (HA f ) 4 V / M rVV-5Mel 107 I4L (R1 g ) 5 V / M rVV-5Mel 110 E3L 6 V/M N/A d 114 C23L 7 V/M N/A d 119 A44L 8 V/M rVV-5Mel 123 C4L 9 V N/A d 126 K1L 10 V N/A d 132 A52R-A53R IGR 11 V N/A d 137 A51R-A56R IGR (Del-III h ) 12 V/M pMVAF #121 146 D4R-D5R IGR 13 V/M MVA-M2-VN 149
DNA Extraction
Viral genomic DNA was extracted from infected cell culture material using the QIAamp DNA Mini Kit (Qiagen, Hilden, Germany) according to the manufacturer's instructions.
Oligonucleotides
The amplification of MLPA probes was carried out with the universal primers (SALSA MLPA forward primer sequence: 5′-6-FAM-GGGTTCCCTAAGGGTTGGA-3′; SALSA MLPA reverse primer sequence: 5′-GTGCCAGCA AGATCCAATCTAGA-3′) included in the SALSA MLPA kit EK5-FAM (MRC Holland, Amsterdam, The Netherlands). VACV-, MVA-, and recombination site-specific MLPA probes were designed to ensure maximum versatility in detecting vaccinia virus strains, including MVA. The vaccinia-specific hybridizing sequences of all MLPA probes were checked by nucleotide BLAST (Altschul et al., 1990) for conservation in all available vaccinia-viral sequences in the National Center for Biotechnology Information (NCBI) nucleotide database (NCBI Resource Coordinators, 2014) and in best possible accordance with MRC Holland synthetic probe design guidelines. Additionally, to avoid nonspecific signals the hybridizing sites were blasted against the Human Genomic and Transcript (Human G+T) database (NCBI Resource Coordinators, 2014) .
The MLPA probes were controlled experimentally by testing reference materials, except for the F14.5L probe pair which was controlled in silico. All MLPA probes are listed in Table 2 . The MLPA probe mix was prepared by mixing 8 μl of each 1 μM MLPA probe solution (left probe oligo + right probe oligo) in a total volume of 600 μl TE (0.01×). Chemically synthesized MLPA probes and primers for amplification of inserted heterologous genes within predefined integration loci (Table 3) were purchased from Metabion (Metabion GmbH, Martinsried, Germany).
MLPA Procedure
The MLPA reaction was performed as described previously (Luber et al., 2012) . Briefly, the MLPA reactions were performed in a 96-Primus advanced Thermocycler device (Peqlab, Erlangen, Germany) using the SALSA MLPA reagents kit EK5-FAM (MRC Holland, Amsterdam, The Netherlands). For hybridization, 5 μl of sample DNA (serial dilutions of 1:100 to 1:1000 in PCR-grade H 2 O) were pipetted into a 500 μl tube, denatured at 95ºC for 5 minutes, and immediately cooled down to 25ºC. Then 3 μl of the hybridization mix (1.5 μl probe mix and 1.5 μl MLPA buffer) were added to the sample, heated for 1 minute at 95ºC, and incubated for 16 hours at 60ºC. The ligation mix (25 μl of PCR-grade H 2 O, 3 μl of Ligase buffer A, 3 μl of Ligase buffer B, 1 μl of Ligase-65) was added to the sample at 60ºC. The ligation reaction was performed at 54ºC for 15 minutes and stopped by heat-inactivation at 98ºC for 5 minutes. The samples were finally cooled down to 4ºC. The PCR reaction was started after adding 10 μl of PCR reaction mix (7.5 μl PCR-grade H 2 O, 2 μl PCR primer mix, and 0.5 μl SALSA polymerase). Thirty-five amplification cycles were carried out at 95ºC for 30 seconds, 60ºC for 30 seconds, and 72ºC for 60 seconds.
Capillary Electrophoresis
Fragment length analysis was performed on an ABI PRISM 3130 genetic analyzer using capillaries (4 × 36 cm) and a POP-7 performance optimized polymer (Applied Biosystems, Foster City, CA). 
Endpoint PCR and Sequencing
Endpoint PCR analysis for amplification of inserted heterologous genes within predefined integration loci was performed using a Mastercycler gradient PCR device (Eppendorf, Hamburg, Germany) and the Qiagen HotStarTaq Master Mix Kit (Qiagen, Hilden, Germany) according to the manufacturers' instructions. The PCR profile has an initial denaturation step at 95ºC for 15 minutes followed by 35 cycles at 94ºC for 30 seconds, 55ºC for 45 seconds, and 72ºC for 1 minute/kb, and a final extension step at 72ºC for 5 minutes. PCR products were separated on 1% agarose gels, excised, and purified using the illustra GFX PCR DNA and Gel Band Purification Kit (GE Healthcare, Chalfont St Giles, UK). Sequencing was performed by GATC Biotech AG, Cologne, Germany.
Results and Discussion
Differentiation Between VACV and MVA Strains (Wild Type and Recombinant) can be Achieved by MLPA PCR Technology All vaccinia viruses, including MVA and MVAderived BAC DNA analyzed, exhibited the pan-vaccinia virus-specific MLPA products E3L (peak #6) and C23L (peak #7) as depicted in Figure 2A -E. Viruses derived from VACV strains (Figures 2A, 2C) exhibited the VACV sequence-specific MLPA products C4L (peak #9), K1L (peak #10), and A52R-A53R IGR (peak #11) that are missing in MVA-derived material ( Figures 2B, 2D-E) .
The versatility of the MLPA probes regarding the capability to detect different VACV strains was implemented in the probe design and was shown for the strains Elstree (Figure 2A Table 2 MLPA Probe Sequences. a LPO: Left probe oligo; RPO: Right probe oligo; b Sequences are indicated in the 5´ → 3´ order; : Phosphate group at the 5´ end of the RPO, has to be added to allow ligation of the LPO to the RPO; Underlined: left flanking sequence of the Del-III locus on the right probe oligo causing a small peak in non-MVA vaccinia viruses. a stronger signal of the MVA sequence-specific MLPA product Del-III (peak #12) as compared to other VACV strains (Figures 2A, 2C) . Note that the two pan-vaccinia virus-specific loci (E3L and C23L) and three VACVspecific loci (C4L, K1L, and A52R-A53R IGR) normally are not used for the insertion of heterologous genes. In this case, however, a particular genetically modified strain of VACV or MVA would be based on the insertion of the heterologous gene into any of these five loci, and the respective MLPA product pattern would alter accordingly. For example, no Del-III peak could be obtained from the bacterial artificial chromosome pMVAF #121 comprising the full-length MVA genome with the pBELO-BAC11 backbone inserted into the Del-III locus ( Figure 2E ). Due to the redundancy of this MLPA module (E3L and C23L being pan-vaccinia virus-specific markers, and C4L, K1L, and A52R-A53R IGR being VACV-specific markers), the distinct differentiation between VACV and MVA strains would even then still be guaranteed.
In general, the authors strongly recommend employing the appropriate positive and negative controls in the form of genomic DNA of VACV and MVA into each run to control the presence and loss of MLPA products and a notemplate control, respectively.
The present MLPA module should also qualify to identify the attenuated vaccinia virus NYVAC strain, in which amongst others the K1L gene has been deleted (Tartaglia et al., 1992) and which is assigned into risk group 1 (U.S. HHS, 2009; ZKBS, 1997) . Due to the lack of NYVACderived reference material, this could not be investigated experimentally. Figure 2 Electropherograms of selected MLPA runs. The peak number grids above the electropherograms show the positions and numbers of peaks according to Table 1 . Size standard: 50-, 75-, 100-, 139-, 150-and 160 base pair peaks. A) Vaccinia virus strain Elstree (wild type). All 13 MLPA peaks are visible. The MVA-and VACV-specific Del-III peak (#12) is less intense (as compared to MVA-derived reference materials [ Figure 1B , D]) due to weak binding of the right half-probe to the left flank of the Del-III progenitor sequence present in all vaccinia viruses; B) Wild type MVA with all 10 MVA specific MLPA fragments. Three VACV specific peaks #9, #10 and #11 are missing. Note the intensity of the MVA-specific peak #12 compared to Figure  1A , C; C) Recombinant VACV strain rVV-5Mel; This strain has insertions in the A56R, I4L and A44L loci (Zajac et al., 2003) which are reflected in the lack of peaks #4, #5 and #8; D) Recombinant MVA strain MVA-M2-VN; Alteration of the D4R locus as described in (Ricci et al., 2011) 
MLPA PCR Technology Allows the Identification of Inserted Heterologous Genes Within Predefined Integration Loci
Insertion of heterologous genes within seven predefined integration loci can be identified by the loss of respective loci-specific MLPA products as shown for recombinant VACV rVV-5Mel and recombinant MVA MVA-M2-VN. VACV rVV-5Mel is a triple recombinant VACV with three different heterologous genes inserted into the predefined loci A56R (peak #4), I4L (peak #5), and A44L (peak #8) (Zajac et al., 2003) . Loss of the respective three locispecific MLPA products is demonstrated in Figure 2C . Recombinant MVA MVA-M2-VN is a single recombinant MVA with the heterologous gene inserted into the predefined locus D4R-D5R IGR (peak #13) (Ricci et al., 2011) . Loss of the respective locus-specific MLPA product is depicted in Figure 2D . All four inserted heterologous genes could be amplified by standard PCR technology using the primers depicted in Table 3 and verified by agarose gel electrophoresis (data not shown).
Limitations of the MLPA PCR Technology
According to MRC Holland guidelines, MLPA probe design is impaired if the targeted genomic sequence has a low GC-content or if the resulting half-probes tend to form secondary structures under the hybridizing step conditions (60ºC, 0.35 M NaCl). Since those impairments are very strong around the six major deletion regions of MVA, only the Del-III locus was implemented into this MLPA module for its apparently prominent use observed in literature research. To achieve this, the border between the left-hand and right-hand hybridizing site of the half-probes on the Del-III locus had to be shifted 15 bases towards the left flank. Therefore, a Del-III MLPA product (peak #12; Figures 2A,  2C ) can be observed in VACV material and can therefore not be used as an MVA-specific marker. Nevertheless, the absence of the peak can be used as a hint for a Del-III alteration ( Figure 2E ). Thus, insertions into the Del-I, -II, -IV, -V, and -VI loci, which are not covered by this MLPA module (Figure 1 ), have to be analyzed by an endpoint PCR approach as described recently (Kremer et al., 2012) . Table 3 Endpoint PCR primers for amplification of heterologous genes within predefined integration loci.
a Target loci are either denominated according to their orthologs in Vaccinia virus strain Western Reserve (NCBI Reference Sequence: NC_006998.1) or the number of the six major deletion regions (Meyer et al., 1991) 
